{"id":46302,"date":"2025-11-11T12:03:09","date_gmt":"2025-11-11T04:03:09","guid":{"rendered":"https:\/\/flcube.com\/?p=46302"},"modified":"2025-11-11T12:03:10","modified_gmt":"2025-11-11T04:03:10","slug":"meiragtx-grants-eli-lilly-worldwide-rights-to-aav%e2%80%91aipl1-gene-therapy-for-lca4","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=46302","title":{"rendered":"MeiraGTx Grants Eli\u202fLilly Worldwide Rights to AAV\u2011AIPL1 Gene Therapy for LCA4"},"content":{"rendered":"\n

MeiraGTx Holdings plc<\/strong> (NASDAQ: MGTX<\/a>) announced a strategic ophthalmology collaboration<\/strong> with Eli Lilly and Company<\/strong> (NYSE: LLY<\/a>). Under the agreement, Lilly receives exclusive worldwide rights<\/strong> to MeiraGTx\u2019s AAV\u2011AIPL1 program<\/strong> targeting Leber Congenital Amaurosis type\u202f4 (LCA4)<\/strong> \u2013 a severe inherited retinal dystrophy caused by deficiency of the aryl\u2011hydrocarbon\u2011interacting protein\u2011like\u202f1 (AIPL1)<\/strong> gene.<\/p>\n\n\n\n

Deal Economics<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Up\u2011front Cash<\/strong><\/td>USD\u202f75\u202fmillion<\/strong> paid to MeiraGTx at signing<\/td><\/tr>
Milestone Potential<\/strong><\/td>>\u202fUSD\u202f400\u202fmillion<\/strong> payable on development, regulatory and commercial milestones<\/td><\/tr>
Royalty Structure<\/strong><\/td>Tiered royalties on net sales of any licensed product (rates disclosed in the definitive agreement)<\/td><\/tr>
Scope<\/strong><\/td>Worldwide exclusive rights to AAV\u2011AIPL1 and to MeiraGTx\u2019s ophthalmology gene\u2011therapy platform<\/strong> (intravitreal capsids, AI\u2011generated promoters, riboswitch technology)<\/td><\/tr>
Target Nomination<\/strong><\/td>Lilly may nominate additional retinal targets for which it will receive the same exclusive rights<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Technology Highlights<\/h2>\n\n\n\n